Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OKYONASDAQ:PLRXNASDAQ:SLGLNASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOKYOOKYO Pharma$2.90-0.3%$1.92$0.81▼$3.11$98.46M-0.09148,855 shs81,432 shsPLRXPliant Therapeutics$1.25+3.8%$1.41$1.10▼$16.10$73.66M1.31.18 million shs1.12 million shsSLGLSol-Gel Technologies$7.39+0.8%$7.42$3.34▼$16.50$20.80M1.0932,953 shs527 shsUNCYUnicycive Therapeutics$4.64-0.1%$6.30$2.02▼$11.00$58.65M1.89265,849 shs819,495 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOKYOOKYO Pharma+11.49%+17.81%+66.29%+140.50%+142.50%PLRXPliant Therapeutics+2.56%-13.04%-16.67%-8.40%-88.68%SLGLSol-Gel Technologies-1.49%-2.74%-0.42%+45.70%-19.06%UNCYUnicycive Therapeutics-5.31%-25.28%-29.95%-21.36%-3.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOKYOOKYO Pharma2.6581 of 5 stars3.53.00.00.03.31.70.0PLRXPliant Therapeutics4.2501 of 5 stars3.04.00.04.72.21.70.6SLGLSol-Gel Technologies2.6959 of 5 stars3.53.00.00.02.21.70.6UNCYUnicycive Therapeutics3.1601 of 5 stars3.83.00.00.02.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOKYOOKYO Pharma 3.00Buy$7.00141.38% UpsidePLRXPliant Therapeutics 2.00Hold$13.31969.28% UpsideSLGLSol-Gel Technologies 3.00Buy$40.00441.27% UpsideUNCYUnicycive Therapeutics 3.50Strong Buy$60.001,194.50% UpsideCurrent Analyst Ratings BreakdownLatest SLGL, OKYO, UNCY, and PLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$90.005/5/2025OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/21/2025UNCYUnicycive TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.004/11/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOKYOOKYO PharmaN/AN/AN/AN/A($0.20) per shareN/APLRXPliant Therapeutics$1.58M48.37N/AN/A$5.00 per share0.25SLGLSol-Gel Technologies$11.54M1.79N/AN/A$10.36 per share0.71UNCYUnicycive Therapeutics$680K86.16N/AN/A$0.72 per share6.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOKYOOKYO Pharma-$16.83MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)PLRXPliant Therapeutics-$210.30M-$3.610.00N/AN/AN/A-67.56%-52.54%8/6/2025 (Estimated)SLGLSol-Gel Technologies-$10.58M-$4.70N/AN/AN/A-107.78%-43.98%-35.28%8/15/2025 (Estimated)UNCYUnicycive Therapeutics-$36.73M-$5.100.00N/AN/AN/A-277.30%-61.53%N/ALatest SLGL, OKYO, UNCY, and PLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/23/2025Q1 2025SLGLSol-Gel TechnologiesN/A-$3.20N/A-$3.20N/A$1.03 million5/14/2025Q1 2025UNCYUnicycive Therapeutics-$1.40-$0.50+$0.90-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOKYOOKYO PharmaN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOKYOOKYO PharmaN/AN/AN/APLRXPliant TherapeuticsN/A11.0311.03SLGLSol-Gel TechnologiesN/A5.125.12UNCYUnicycive TherapeuticsN/A1.641.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOKYOOKYO Pharma2.97%PLRXPliant Therapeutics97.30%SLGLSol-Gel Technologies26.18%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipOKYOOKYO Pharma40.46%PLRXPliant Therapeutics8.00%SLGLSol-Gel Technologies66.51%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOKYOOKYO Pharma733.84 million20.15 millionNot OptionablePLRXPliant Therapeutics9061.39 million56.48 millionOptionableSLGLSol-Gel Technologies502.79 million933,000OptionableUNCYUnicycive Therapeutics912.64 million11.29 millionNot OptionableSLGL, OKYO, UNCY, and PLRX HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 2 at 10:00 AM | prnewswire.comUnicycive hit with CRL on oxylanthanum carbonate NDAJuly 1 at 3:25 PM | thepharmaletter.comTKaplan Fox & Kilsheimer LLP is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law ViolationsJuly 1 at 4:36 AM | theglobeandmail.comUnicycive Therapeutics, Inc. (UNCY) - Yahoo FinanceJune 30 at 11:36 PM | finance.yahoo.comFDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospectJune 30 at 6:35 PM | fiercepharma.comFUnicycive receives CRL for oxylanthanum carbonate NDA for hyperphosphatemiaJune 30 at 6:35 PM | msn.comUnicycive stock falls after FDA issues Complete Response LetterJune 30 at 6:35 PM | investing.comUnicycive Shares Slide Premarket as FDA Rejects Oxylanthanum Carbonate ApplicationJune 30 at 6:35 PM | marketwatch.comUnicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease ...June 30 at 6:35 PM | finance.yahoo.comUnicycive Shares Sink After FDA Issues Response Letter on Kidney Drug FilingJune 30 at 6:35 PM | msn.comINVESTOR ALERT: Investigation of Unicycive Therapeutics, Inc. (UNCY) Announced by Holzer & Holzer, LLCJune 30 at 12:58 PM | globenewswire.comUnicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on DialysisJune 30 at 7:05 AM | globenewswire.comUnicycive Therapeutics Inc News (UNCY) - Investing.comJune 24, 2025 | investing.comUnicycive Therapeutics (NASDAQ:UNCY) Shares Gap Down - Time to Sell?June 20, 2025 | marketbeat.comUnicycive Therapeutics Inc trading halted, news pendingJune 18, 2025 | msn.comUnicycive to implement 1-for-10 reverse stock split to regain Nasdaq listingJune 18, 2025 | investing.comUnicycive Therapeutics, Inc. Announces Reverse Stock SplitJune 17, 2025 | globenewswire.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 46.4% in MayJune 15, 2025 | marketbeat.comUNCY Q3 EPS Forecast Raised by Brookline Capital ManagementJune 12, 2025 | marketbeat.comKaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law ViolationsJune 11, 2025 | theglobeandmail.comRetail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28mJune 11, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLGL, OKYO, UNCY, and PLRX Company DescriptionsOKYO Pharma NASDAQ:OKYO$2.90 -0.01 (-0.34%) Closing price 03:00 PM EasternExtended Trading$2.92 +0.02 (+0.66%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Pliant Therapeutics NASDAQ:PLRX$1.25 +0.05 (+3.75%) Closing price 03:40 PM EasternExtended Trading$1.25 0.00 (0.00%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Sol-Gel Technologies NASDAQ:SLGL$7.39 +0.06 (+0.82%) As of 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Unicycive Therapeutics NASDAQ:UNCY$4.64 -0.01 (-0.11%) Closing price 03:57 PM EasternExtended Trading$4.62 -0.02 (-0.43%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
